Slide 1: Q1 2023 Results
April 28, 2023 Q1 2023 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO APTAR COMMUNICATIONS GUIDEBOOK
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q1 2023 Financial Highlights
Q1 2023 Financial Highlights Highlights: +2% Reported Sales Growth +4% Core Sales Growth* • Very positive start to 2023, driven by core sales growth in our Pharma and Beauty segments • Pharma results were driven by increased demand for our proprietary dispensing devices, which had core sales growth
Slide 4: A Sustainable, Socially Responsible Company
A Sustainable, Socially Responsible Company Logo above reprinted with permission of Barron’s Barron’s Forbes Newsweek CDP EcoVadis In the Top 100 One of the In the Top 100 Recognized as a Sustainability Rating Most Sustainable World’s Top Female America’s Most Supplier Engagement Platinum Companies
Slide 5: Capital Allocation
Capital Allocation Highlights • For 2023, we expect our capital expenditures to be in the range of $280 to $300 million, due to additional, accelerated investment we will be making to increase production capacity for our proprietary pharma dispensing devices to meet rapidly growing customer demand •
Slide 6: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Pharma Aptar Beauty Aptar Closures • Our elastomeric components have been • In Europe, our prestige fragrance contributed to our • Our custom inverted closure with a self- selected for use on GLP-1 injectable growth in the quarter and
Slide 7: First Quarter 2023 Reported Results
First Quarter 2023 Reported Results Reported ReportedQ1 Sales Q Sales Q1Sales Reported Q EPS (in millions $) Q1 Highlights $1,000 $1.20 $845 2% $860 $1.00 $0.93 -12% • Aptar Pharma’s core sales growth was driven $800 $0.82 $0.80 by healthy demand for its proprietary $600 $0.60 dispensing devices use
Slide 8: First Quarter 2023 Adj. EPS and Adj. EBITDA
First Quarter 2023 Adj. EPS and Adj. EBITDA 28% 26% Q1 2022 Q1 2023 Adjustments: Effective Tax Effective Tax • 2022: Restructuring initiatives of $0.3 mil; Net Rate Adjusted Rate Adjusted unrealized investment loss of $2.1 mil Earnings* Earnings* • 2023: Restructuring initiatives of $11.5 mil; Net u
Slide 9: Outlook
Outlook Outlook Highlights Earnings Per Share 26-28% • Anticipate our strong momentum continuing, and expect $1.40 our proprietary pharma dispensing devices and beauty $1.11 – $1.19 solutions to grow $1.20 $1.00 $0.95 $0.98 Q2 expected • Our injectables division’s performance should improve as the d
Slide 10: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 10